Stay updated with breaking news from Pharma Partner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal - Sibnayal will be marketed to one-third of European patients by three members